Novo wins Saxenda OK in Canada; Novartis scores CHMP nod for Zykadia;

@FiercePharma: ICYMI from FiercePharmaManufacturing: Impax reports significant jump in revenues as it gets plant problems behind it. Article | Follow @FiercePharma

@EricPFierce: FDA problems continue to pile up at Wockhardt Indian plant banned from shipping to the US. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI earlier: Pfizer, Novartis get MenB ACIP nod--but not the one they're really after. More from FierceVaccines | Follow @CarlyHFierce

> Novo Nordisk ($NVO) has received Canadian approval for weight-loss drug Saxenda. Report

> The European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended Novartis' ($NVS) lung cancer drug Zykadia in patients with ALK+ non-small cell lung cancer previously treated with Pfizer's ($PFE) Xalkori. Report

> Amarin has signed an exclusive agreement with Eddingpharm to develop and commercialize Vascepa in mainland China, Hong Kong and the Macao Special Administrative Regions and Taiwan. More

Medical Device News

@FierceMedDev: Exact Sciences beefs up sales and reimbursement efforts for colon cancer Dx. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Boston Scientific launches upgraded endoscope, says it will reduce repeat procedures. Article | Follow @VarunSaxena2

@EmilyWFierce: Vigilant Biosciences reels in $5.5M for oral cancer test. More from FierceDiagnostics | Follow @EmilyWFierce

> Nikon to buy optical imaging player Optos for $400M in med tech expansion bid. Story

> UnitedHealth to require prior authorization for gynecological procedures amid morcellator pushback. More

> Device for remote and autonomous management of Parkinson's being tested in Europe. Article

Biotech News

@FierceBiotech: From @FiercePharmAsia, Novartis' Japan unit hit with a 15-day sales ban. Article | Follow @FierceBiotech

@JohnCFierce: ICYMI: Vitae slammed as another BACE inhibitor trips and Boehringer halts Alzheimer's study. Report | Follow @JohnCFierce

@DamianFierce: While $MRK and $ACT embrace antibiotics, $AZN is tiptoeing out. Report | Follow @DamianFierce

> Viehbacher wades into the startup world, joining PureTech in his first post-Sanofi move. News

> Chiasma hauls in $70M to write its post-Roche future. Report

> Ablynx gets caught in Merck KGaA's R&D retreat. Story

> Stealthy Lyric Pharma bags $20M for its gastro drug. Article